Beranda › Karsinoma Epitel Ovarium
Uji klinis Karsinoma Epitel Ovarium yang merekrut di AS
26 studi untuk Karsinoma Epitel Ovarium merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Boston, MA8 studi
- Durham, NC8 studi
- Chicago, IL7 studi
- San Diego, CA7 studi
- New York City, NY7 studi
- Philadelphia, PA6 studi
- Baltimore, MD6 studi
- Houston, TX6 studi
- Cleveland, OH6 studi
- Portland, OR5 studi
- Los Angeles, CA5 studi
- Minneapolis, MN5 studi
- Edison, NJ5 studi
- Salt Lake City, UT5 studi
- New Haven, CT4 studi
- St. Louis, MO4 studi
- San Antonio, TX4 studi
- Seattle, WA4 studi
- Birmingham, AL4 studi
- Arlington, VA4 studi
- Queens, NY4 studi
- Dallas, TX4 studi
- Columbus, OH3 studi
- Oklahoma City, OK3 studi
- Rochester, MN3 studi
- Mountain View, CA3 studi
- Clifton, NJ3 studi
- Nashville, TN3 studi
- Grand Rapids, MI3 studi
- New Orleans, LA3 studi
- Sioux Falls, SD3 studi
- West Palm Beach, FL3 studi
- Washington, DC3 studi
- Billings, MT3 studi
- Dayton, OH3 studi
- Indianapolis, IN3 studi
- Aurora, CO3 studi
- Providence, RI3 studi
- San Francisco, CA3 studi
- Shreveport, LA3 studi
Berdasarkan negara bagian
- Alabama4 studi
- Arizona4 studi
- California10 studi
- Colorado4 studi
- Connecticut4 studi
- Florida11 studi
- Georgia3 studi
- Illinois8 studi
- Indiana3 studi
- Louisiana4 studi
- Maryland7 studi
- Massachusetts9 studi
- Michigan5 studi
- Minnesota7 studi
- Missouri5 studi
- Montana3 studi
- New Jersey9 studi
- New York10 studi
- North Carolina9 studi
- Ohio10 studi
- Oklahoma3 studi
- Oregon6 studi
- Pennsylvania10 studi
- Rhode Island3 studi
- South Dakota3 studi
- Tennessee6 studi
- Texas12 studi
- Utah5 studi
- Virginia6 studi
- Washington6 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 1 Okt 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 29 Sep 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05867251Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 15 Sep 2026 · NCT06915025A Study of Isoquercetin in People With Ovarian Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07303894ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
Menerima pesertaStudi observasional
Usia 18 ke atas · Wanita · Diperbarui 17 Agu 2026 · NCT07764133Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Menerima peserta
Usia 18 ke atas · Wanita · Diperbarui 6 Agu 2026 · NCT06386887AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 21 Jul 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 2 Jul 2026 · NCT06819007A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Menerima peserta
Usia 18 ke atas · Wanita · Diperbarui 1 Jul 2026 · NCT05429970[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Menerima pesertaFase 1/2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT07432633CT-95 in Advanced Cancers Associated With Mesothelin Expression
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT06756035Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 19 Mei 2026 · NCT06305299Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Apr 2026 · NCT05297734A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 7 Apr 2026 · NCT04516447A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 3 Feb 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 23 Des 2025 · NCT06690775Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Menerima pesertaStudi observasional
Usia 30 ke atas · Wanita · Diperbarui 16 Sep 2025 · NCT04794322A Study of NX-1607 in Adults With Advanced Malignancies
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT05107674Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Agu 2025 · NCT04429542A Beta-only IL-2 ImmunoTherapY Study
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2025 · NCT05086692BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Mar 2025 · NCT04196257Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 80 · Wanita · Diperbarui 28 Feb 2025 · NCT00005095Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.